|
Gene: ILF2 |
Gene summary for ILF2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ILF2 | Gene ID | 3608 |
Gene name | interleukin enhancer binding factor 2 | |
Gene Alias | NF45 | |
Cytomap | 1q21.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DY09 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3608 | ILF2 | NCCBC2 | Human | Breast | DCIS | 6.13e-03 | -2.02e-01 | 0.1554 |
3608 | ILF2 | NCCBC5 | Human | Breast | DCIS | 4.14e-12 | -8.50e-02 | 0.2046 |
3608 | ILF2 | P1 | Human | Breast | IDC | 2.20e-18 | -4.30e-01 | 0.1527 |
3608 | ILF2 | P2 | Human | Breast | IDC | 4.70e-09 | 3.89e-01 | 0.21 |
3608 | ILF2 | DCIS2 | Human | Breast | DCIS | 9.28e-56 | 7.53e-02 | 0.0085 |
3608 | ILF2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.58e-03 | 2.06e-01 | 0.0155 |
3608 | ILF2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.06e-02 | 4.85e-01 | 0.0216 |
3608 | ILF2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.15e-09 | 5.49e-01 | -0.0811 |
3608 | ILF2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.32e-05 | 3.42e-01 | -0.1088 |
3608 | ILF2 | HTA11_347_2000001011 | Human | Colorectum | AD | 9.43e-18 | 4.95e-01 | -0.1954 |
3608 | ILF2 | HTA11_411_2000001011 | Human | Colorectum | SER | 8.05e-03 | 6.18e-01 | -0.2602 |
3608 | ILF2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.43e-04 | 4.72e-01 | -0.1207 |
3608 | ILF2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.48e-17 | 6.26e-01 | -0.1464 |
3608 | ILF2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.29e-24 | 8.60e-01 | -0.059 |
3608 | ILF2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 4.60e-03 | 4.06e-01 | -0.1706 |
3608 | ILF2 | HTA11_546_2000001011 | Human | Colorectum | AD | 7.99e-03 | 3.80e-01 | -0.0842 |
3608 | ILF2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.77e-04 | 3.20e-01 | -0.0179 |
3608 | ILF2 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.22e-21 | 6.64e-01 | 0.096 |
3608 | ILF2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.34e-02 | 3.57e-01 | 0.0528 |
3608 | ILF2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.00e-07 | 6.98e-01 | 0.0131 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ILF2 | SNV | Missense_Mutation | c.1170G>T | p.Glu390Asp | p.E390D | Q12905 | protein_coding | tolerated_low_confidence(0.06) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ILF2 | SNV | Missense_Mutation | c.910C>A | p.Leu304Ile | p.L304I | Q12905 | protein_coding | deleterious(0.02) | possibly_damaging(0.871) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ILF2 | SNV | Missense_Mutation | c.890N>C | p.Arg297Thr | p.R297T | Q12905 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-C8-A12V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ILF2 | SNV | Missense_Mutation | rs767092802 | c.725C>T | p.Pro242Leu | p.P242L | Q12905 | protein_coding | deleterious(0.03) | possibly_damaging(0.543) | TCGA-D8-A1Y3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD |
ILF2 | SNV | Missense_Mutation | novel | c.119C>T | p.Ala40Val | p.A40V | Q12905 | protein_coding | tolerated(0.3) | benign(0.076) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ILF2 | SNV | Missense_Mutation | novel | c.937N>G | p.Thr313Ala | p.T313A | Q12905 | protein_coding | deleterious(0.04) | possibly_damaging(0.863) | TCGA-PL-A8LX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ILF2 | SNV | Missense_Mutation | novel | c.644C>T | p.Ala215Val | p.A215V | Q12905 | protein_coding | deleterious(0.04) | possibly_damaging(0.777) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ILF2 | SNV | Missense_Mutation | rs768322800 | c.481N>A | p.Glu161Lys | p.E161K | Q12905 | protein_coding | tolerated(0.09) | benign(0.392) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ILF2 | SNV | Missense_Mutation | c.493G>A | p.Glu165Lys | p.E165K | Q12905 | protein_coding | tolerated(0.11) | benign(0.211) | TCGA-AY-6196-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ILF2 | SNV | Missense_Mutation | c.1155N>A | p.Ser385Arg | p.S385R | Q12905 | protein_coding | deleterious_low_confidence(0.03) | benign(0.207) | TCGA-CM-4744-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |